CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

Background - - CT-guided high-dose-rate (HDR) brachytherapy (hereafter, HDR brachytherapy) has been shown to be safe and effective for patients with unresectable hepatocellular carcinoma (HCC), but studies comparing this therapy with other local-regional therapies are scarce. - - Purpose - - To c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Auer, Timo Alexander (VerfasserIn) , Müller, Lukas (VerfasserIn) , Schulze, Daniel (VerfasserIn) , Anhamm, Melina (VerfasserIn) , Bettinger, Dominik (VerfasserIn) , Wagner, Verena (VerfasserIn) , Haubold, Johannes (VerfasserIn) , Zopfs, David (VerfasserIn) , Pinto dos Santos, Daniel (VerfasserIn) , Eisenblätter, Michel (VerfasserIn) , Gebauer, Bernhard (VerfasserIn) , Kloeckner, Roman (VerfasserIn) , Collettini, Federico (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: February 2024
In: Radiology
Year: 2024, Jahrgang: 310, Heft: 2, Pages: 1-9
ISSN:1527-1315
DOI:10.1148/radiol.232044
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1148/radiol.232044
Verlag, kostenfrei, Volltext: https://pubs.rsna.org/doi/10.1148/radiol.232044
Volltext
Verfasserangaben:Timo A. Auer, MD, Lukas Müller, MD, PhD, Daniel Schulze, MS, PhD, Melina Anhamm, Dominik Bettinger, MD, Verena Steinle, MD, Johannes Haubold, MD, David Zopfs, MD, Daniel Pinto dos Santos, MD, Michel Eisenblätter, MD, PhD, Bernhard Gebauer, MD, Roman Kloeckner, MD, Federico Collettini, MD

MARC

LEADER 00000caa a2200000 c 4500
001 1918503699
003 DE-627
005 20250716233743.0
007 cr uuu---uuuuu
008 250225s2024 xx |||||o 00| ||eng c
024 7 |a 10.1148/radiol.232044  |2 doi 
035 |a (DE-627)1918503699 
035 |a (DE-599)KXP1918503699 
035 |a (OCoLC)1528019684 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Auer, Timo Alexander  |d 1989-  |e VerfasserIn  |0 (DE-588)1138041424  |0 (DE-627)895404281  |0 (DE-576)492316686  |4 aut 
245 1 0 |a CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma  |c Timo A. Auer, MD, Lukas Müller, MD, PhD, Daniel Schulze, MS, PhD, Melina Anhamm, Dominik Bettinger, MD, Verena Steinle, MD, Johannes Haubold, MD, David Zopfs, MD, Daniel Pinto dos Santos, MD, Michel Eisenblätter, MD, PhD, Bernhard Gebauer, MD, Roman Kloeckner, MD, Federico Collettini, MD 
264 1 |c February 2024 
300 |b Illustrationen 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online veröffentlicht: 6. Februar 2024 
500 |a Gesehen am 25.02.2025 
520 |a Background - - CT-guided high-dose-rate (HDR) brachytherapy (hereafter, HDR brachytherapy) has been shown to be safe and effective for patients with unresectable hepatocellular carcinoma (HCC), but studies comparing this therapy with other local-regional therapies are scarce. - - Purpose - - To compare patient outcomes of HDR brachytherapy and transarterial chemoembolization (TACE) in patients with unresectable HCC. - - Materials and Methods - - This multi-institutional retrospective study included consecutive treatment-naive adult patients with unresectable HCC who underwent either HDR brachytherapy or TACE between January 2010 and December 2022. Overall survival (OS) and progression-free survival (PFS) were compared between patients matched for clinical and tumor characteristics by propensity score matching. Not all patients who underwent TACE had PFS available; thus, a different set of patients was used for PFS and OS analysis for this treatment. Hazard ratios (HRs) were calculated from Kaplan-Meier survival curves. - - Results - - After propensity matching, 150 patients who underwent HDR brachytherapy (median age, 71 years [IQR, 63-77 years]; 117 males) and 150 patients who underwent TACE (OS analysis median age, 70 years [IQR, 63-77 years]; 119 male; PFS analysis median age, 68 years [IQR: 63-76 years]; 119 male) were analyzed. Hazard of death was higher in the TACE versus HDR brachytherapy group (HR, 4.04; P < .001). Median estimated PFS was 32.8 months (95% CI: 12.5, 58.7) in the HDR brachytherapy group and 11.6 months (95% CI: 4.9, 22.7) in the TACE group. Hazard of disease progression was higher in the TACE versus HDR brachytherapy group (HR, 2.23; P < .001). - - Conclusion - - In selected treatment-naive patients with unresectable HCC, treatment with CT-guided HDR brachytherapy led to improved OS and PFS compared with TACE. 
700 1 |a Müller, Lukas  |e VerfasserIn  |4 aut 
700 1 |a Schulze, Daniel  |e VerfasserIn  |4 aut 
700 1 |a Anhamm, Melina  |e VerfasserIn  |4 aut 
700 1 |a Bettinger, Dominik  |e VerfasserIn  |4 aut 
700 1 |a Wagner, Verena  |d 1991-  |e VerfasserIn  |0 (DE-588)1213912830  |0 (DE-627)1724943006  |4 aut 
700 1 |a Haubold, Johannes  |e VerfasserIn  |4 aut 
700 1 |a Zopfs, David  |e VerfasserIn  |4 aut 
700 1 |a Pinto dos Santos, Daniel  |e VerfasserIn  |4 aut 
700 1 |a Eisenblätter, Michel  |e VerfasserIn  |4 aut 
700 1 |a Gebauer, Bernhard  |e VerfasserIn  |4 aut 
700 1 |a Kloeckner, Roman  |e VerfasserIn  |4 aut 
700 1 |a Collettini, Federico  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Radiology  |d Oak Brook, Ill. : Soc., 1923  |g 310(2024), 2 vom: Feb., Artikel-ID e232044, Seite 1-9  |h Online-Ressource  |w (DE-627)320487253  |w (DE-600)2010588-5  |w (DE-576)094056706  |x 1527-1315  |7 nnas  |a CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma 
773 1 8 |g volume:310  |g year:2024  |g number:2  |g month:02  |g elocationid:e232044  |g pages:1-9  |g extent:9  |a CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma 
856 4 0 |u https://doi.org/10.1148/radiol.232044  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://pubs.rsna.org/doi/10.1148/radiol.232044  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250225 
993 |a Article 
994 |a 2024 
998 |g 1213912830  |a Wagner, Verena  |m 1213912830:Wagner, Verena  |d 910000  |d 911400  |e 910000PW1213912830  |e 911400PW1213912830  |k 0/910000/  |k 1/910000/911400/  |p 6 
999 |a KXP-PPN1918503699  |e 4672416046 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"February 2024"}],"id":{"doi":["10.1148/radiol.232044"],"eki":["1918503699"]},"name":{"displayForm":["Timo A. Auer, MD, Lukas Müller, MD, PhD, Daniel Schulze, MS, PhD, Melina Anhamm, Dominik Bettinger, MD, Verena Steinle, MD, Johannes Haubold, MD, David Zopfs, MD, Daniel Pinto dos Santos, MD, Michel Eisenblätter, MD, PhD, Bernhard Gebauer, MD, Roman Kloeckner, MD, Federico Collettini, MD"]},"physDesc":[{"extent":"9 S.","noteIll":"Illustrationen"}],"relHost":[{"name":{"displayForm":["The Radiological Society of North America"]},"id":{"eki":["320487253"],"zdb":["2010588-5"],"issn":["1527-1315"]},"origin":[{"publisherPlace":"Oak Brook, Ill.","dateIssuedDisp":"1923-","publisher":"Soc.","dateIssuedKey":"1923"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Radiology","title":"Radiology"}],"corporate":[{"display":"Radiological Society of North America","roleDisplay":"Herausgebendes Organ","role":"isb"}],"language":["eng"],"recId":"320487253","disp":"CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinomaRadiology","note":["Fortsetzung der Druck-Ausgabe","Gesehen 07.11.22"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"extent":"9","volume":"310","text":"310(2024), 2 vom: Feb., Artikel-ID e232044, Seite 1-9","pages":"1-9","issue":"2","year":"2024"},"pubHistory":["1.1923 -"]}],"title":[{"title":"CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma","title_sort":"CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma"}],"person":[{"role":"aut","display":"Auer, Timo Alexander","roleDisplay":"VerfasserIn","given":"Timo Alexander","family":"Auer"},{"role":"aut","display":"Müller, Lukas","roleDisplay":"VerfasserIn","given":"Lukas","family":"Müller"},{"roleDisplay":"VerfasserIn","display":"Schulze, Daniel","role":"aut","family":"Schulze","given":"Daniel"},{"role":"aut","display":"Anhamm, Melina","roleDisplay":"VerfasserIn","given":"Melina","family":"Anhamm"},{"given":"Dominik","family":"Bettinger","role":"aut","roleDisplay":"VerfasserIn","display":"Bettinger, Dominik"},{"display":"Wagner, Verena","roleDisplay":"VerfasserIn","role":"aut","family":"Wagner","given":"Verena"},{"family":"Haubold","given":"Johannes","display":"Haubold, Johannes","roleDisplay":"VerfasserIn","role":"aut"},{"given":"David","family":"Zopfs","role":"aut","roleDisplay":"VerfasserIn","display":"Zopfs, David"},{"given":"Daniel","family":"Pinto dos Santos","role":"aut","roleDisplay":"VerfasserIn","display":"Pinto dos Santos, Daniel"},{"given":"Michel","family":"Eisenblätter","role":"aut","display":"Eisenblätter, Michel","roleDisplay":"VerfasserIn"},{"display":"Gebauer, Bernhard","roleDisplay":"VerfasserIn","role":"aut","family":"Gebauer","given":"Bernhard"},{"family":"Kloeckner","given":"Roman","display":"Kloeckner, Roman","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Collettini, Federico","given":"Federico","family":"Collettini"}],"note":["Online veröffentlicht: 6. Februar 2024","Gesehen am 25.02.2025"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1918503699","language":["eng"]} 
SRT |a AUERTIMOALCTGUIDEDHI2024